TNFRSF17 and plasma cell myeloma: These data have highlighted BCMA as an attractive target in myeloma; however, studies have also demonstrated that normal plasma cells can survive BCMA suppression, thought mainly via a compensatory mechanism of upregulation of its co-family receptor TACI [69].